Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Gain Therapeutics, Inc. (GANX : NSDQ)

• Company Description    Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $1.66 Daily Weekly Monthly 20 Day Moving Average: 588,973 shares Shares Outstanding: 35.95 (millions) Market Capitalization: $59.68 (millions) Beta: 0.14 52 Week High: $3.19 52 Week Low: $1.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.79% 5.90% 12 Week -7.26% -15.76% Year To Date -23.15% -28.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4800 MONTGOMERY LANE SUITE 220 - BETHESDA,MD 20814 USA ph: 301-500-1556 fax: - ajammu@gaintherapeutics.com http://www.gaintherapeutics.com

• General Corporate Information    Officers Gene Mack - Chief Executive Officer and Director Khalid Islam - Chairman Gianluca Fuggetta - Senior Vice President Finance Dov Goldstein - Director Hans Peter Hasler - Director Peer Information Gain Therapeutics, Inc. (GSAC) Gain Therapeutics, Inc. (CASI) Gain Therapeutics, Inc. (ALCD.) Gain Therapeutics, Inc. (OMNN) Gain Therapeutics, Inc. (CGPI.) Gain Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 36269B105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 35.95 Most Recent Split Date: (:1) Beta: 0.14 Market Capitalization: $59.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 13.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 54.76% vs. Previous Quarter: -18.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -289.10 03/31/25 - -247.55 12/31/24 - -222.61 ROA 06/30/25 - -155.11 03/31/25 - -146.06 12/31/24 - -135.48 Current Ratio 06/30/25 - 1.79 03/31/25 - 2.22 12/31/24 - 2.97 Quick Ratio 06/30/25 - 1.79 03/31/25 - 2.22 12/31/24 - 2.97 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.12 03/31/25 - 0.20 12/31/24 - 0.28 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.09 03/31/25 - 0.05 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - 8.08 03/31/25 - 5.15 12/31/24 - 4.28

Powered by Zacks Investment Research ©